CVRx (NASDAQ:CVRX) Price Target Lowered to $12.00 at Lake Street Capital

CVRx (NASDAQ:CVRX) had its price target cut by Lake Street Capital from $18.00 to $12.00 in a research report released on Thursday, Marketbeat.com reports. They currently have a buy rating on the stock.

Several other equities analysts have also issued reports on CVRX. Canaccord Genuity Group dropped their target price on shares of CVRx from $32.00 to $14.00 and set a buy rating on the stock in a report on Wednesday, May 1st. William Blair lowered shares of CVRx from an outperform rating to a market perform rating in a report on Wednesday, May 1st. Piper Sandler dropped their target price on shares of CVRx from $33.00 to $15.00 and set an overweight rating on the stock in a report on Wednesday, May 1st. JPMorgan Chase & Co. lowered shares of CVRx from an overweight rating to a neutral rating and dropped their target price for the company from $36.00 to $13.00 in a report on Wednesday, May 1st. Finally, Craig Hallum began coverage on shares of CVRx in a report on Wednesday, May 1st. They issued a buy rating and a $23.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, CVRx currently has an average rating of Moderate Buy and an average price target of $13.80.

CVRx Stock Performance

Shares of CVRx stock opened at $8.51 on Thursday. The company has a quick ratio of 10.87, a current ratio of 12.18 and a debt-to-equity ratio of 0.44. CVRx has a twelve month low of $6.40 and a twelve month high of $33.13. The stock has a market cap of $183.82 million, a price-to-earnings ratio of -3.45 and a beta of 1.27. The company’s fifty day moving average is $9.27 and its 200 day moving average is $17.63.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.51). CVRx had a negative return on equity of 66.05% and a negative net margin of 123.58%. The business had revenue of $10.77 million during the quarter, compared to the consensus estimate of $11.60 million. Sell-side analysts forecast that CVRx will post -2.39 EPS for the current year.

Hedge Funds Weigh In On CVRx

Institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new position in shares of CVRx during the fourth quarter valued at about $102,000. Trexquant Investment LP bought a new stake in shares of CVRx during the fourth quarter worth about $426,000. Jump Financial LLC bought a new stake in shares of CVRx during the fourth quarter worth about $499,000. Valeo Financial Advisors LLC bought a new stake in shares of CVRx during the first quarter worth about $346,000. Finally, FourWorld Capital Management LLC bought a new stake in shares of CVRx during the first quarter worth about $374,000. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.